Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 14/20 | 0.67 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863284 | 0.92 | GPR52 (0.59) | GPR52S1PR5S1PR4NR4A2MEN1 | |
| SCHEMBL3200888 | 0.91 | GPR52 (0.68) | GPR52S1PR5S1PR4 | |
| SCHEMBL1853402 | 0.91 | GPR52 (0.75) | GPR52S1PR5S1PR4NR4A2 | |
| SCHEMBL1849113 | 0.88 | GPR52 (0.63) | GPR52S1PR5S1PR4 | |
| SCHEMBL1854179 | 0.87 | GPR52 (0.62) | GPR52S1PR5S1PR4MEN1ALDH1A1 | |
| SCHEMBL1848356 | 0.87 | GPR52 (0.62) | GPR52S1PR5S1PR4 | |
| SCHEMBL3221421 | 0.87 | GPR52 (0.57) | GPR52S1PR5S1PR4NR4A2PTGER4 | |
| SCHEMBL3196520 | 0.86 | GPR52 (0.86) | GPR52S1PR5S1PR4 | |
| SCHEMBL1849743 | 0.86 | GPR52 (0.61) | GPR52S1PR5S1PR4 | |
| SCHEMBL3198653 | 0.86 | GPR52 (0.56) | GPR52S1PR5S1PR4PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885S1PR5 696/4885S1PR4 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.